<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:51:01 -0700</creation_date>
  <update_date>2013-05-27 11:29:50 -0600</update_date>
  <accession>HMDBP00636</accession>
  <secondary_accessions>
    <accession>5908</accession>
    <accession>HMDBP04369</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>DPDE3</synonym>
    <synonym>PDE43</synonym>
  </synonyms>
  <gene_name>PDE4D</gene_name>
  <general_function>Involved in catalytic activity</general_function>
  <specific_function>Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
</specific_function>
  <pathways>
    <pathway>
      <name>3',5'-cyclic AMP degradation</name>
      <smpdb_id/>
      <kegg_map_id/>
    </pathway>
    <pathway>
      <name>Purine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00230</kegg_map_id>
    </pathway>
    <pathway>
      <name>Morphine addiction</name>
      <smpdb_id/>
      <kegg_map_id>map05032</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00058</accession>
      <name>Cyclic AMP</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00547</accession>
      <name>Magnesium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01333</accession>
      <name>Manganese</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00045</accession>
      <name>Adenosine monophosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01314</accession>
      <name>Cyclic GMP</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01397</accession>
      <name>Guanosine monophosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00674</accession>
      <name>PA(16:0/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB07858</accession>
      <name>PA(16:0/18:1(11Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB07859</accession>
      <name>PA(16:0/18:1(9Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB07860</accession>
      <name>PA(16:0/18:2(9Z,12Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB07861</accession>
      <name>PA(18:0/18:2(9Z,12Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB07862</accession>
      <name>PA(18:1(11Z)/18:1(11Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB07863</accession>
      <name>PA(18:1(11Z)/18:1(9Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB07864</accession>
      <name>PA(18:1(9Z)/18:1(11Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB07865</accession>
      <name>PA(18:1(9Z)/18:1(9Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11145</accession>
      <name>PA(16:0e/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11155</accession>
      <name>PA(P-16:0e/18:2(9Z,12Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11156</accession>
      <name>PA(20:4(5Z,8Z,11Z,14Z)e/2:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14789</accession>
      <name>Dyphylline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15056</accession>
      <name>Ketotifen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15220</accession>
      <name>Iloprost</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15614</accession>
      <name>Ibudilast</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on ester bonds</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>phosphoric ester hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>phosphoric diester hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cyclic-nucleotide phosphodiesterase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>3',5'-cyclic-nucleotide phosphodiesterase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>biological regulation</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of biological process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of cellular process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signal transduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytosol</description>
      <go_id>GO:0005829</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>membrane</description>
      <go_id>GO:0016020</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>microtubule organizing center</description>
      <go_id>GO:0005815</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>3',5'-cyclic-AMP phosphodiesterase activity</description>
      <go_id>GO:0004115</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>cAMP binding</description>
      <go_id>GO:0030552</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>drug binding</description>
      <go_id>GO:0008144</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>metal ion binding</description>
      <go_id>GO:0046872</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cAMP catabolic process</description>
      <go_id>GO:0006198</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>establishment of endothelial barrier</description>
      <go_id>GO:0061028</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>signal transduction</description>
      <go_id>GO:0007165</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>smooth muscle contraction</description>
      <go_id>GO:0006939</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cytoplasm</subcellular_location>
    <subcellular_location>Membrane</subcellular_location>
    <subcellular_location>Cytoplasm</subcellular_location>
    <subcellular_location>cytoskeleton</subcellular_location>
    <subcellular_location>Cytoplasm</subcellular_location>
    <subcellular_location>cytoskeleton</subcellular_location>
    <subcellular_location>centrosome</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>5</chromosome_location>
    <locus>5q12</locus>
    <gene_sequence>&gt;2430 bp
ATGGAGGCAGAGGGCAGCAGCGCGCCGGCCCGGGCGGGCAGCGGAGAGGGCAGCGACAGC
GCCGGCGGGGCCACGCTCAAAGCCCCCAAGCATCTCTGGAGGCACGAGCAGCACCACCAG
TACCCGCTCCGGCAGCCCCAGTTCCGCCTCCTGCATCCCCATCACCACCTGCCCCCGCCG
CCGCCACCCTCGCCCCAGCCCCAGCCCCAGTGTCCGCTACAGCCGCCGCCGCCGCCCCCC
CTGCCGCCGCCCCCGCCGCCGCCCGGGGCTGCCCGCGGCCGCTACGCCTCGAGCGGGGCC
ACCGGCCGCGTCCGGCATCGCGGCTACTCGGACACCGAGCGCTACCTGTACTGTCGCGCC
ATGGACCGCACCTCCTACGCGGTGGAGACCGGCCACCGGCCCGGCCTGAAGAAATCCAGG
ATGTCCTGGCCCTCCTCGTTCCAGGGACTCAGGCGTTTTGATGTGGACAATGGCACATCT
GCGGGACGGAGTCCCTTGGATCCCATGACCAGCCCAGGATCCGGGCTAATTCTCCAAGCA
AATTTTGTCCACAGTCAACGACGGGAGTCCTTCCTGTATCGATCCGACAGCGATTATGAC
CTCTCTCCAAAGTCTATGTCCCGGAACTCCTCCATTGCCAGTGATATACACGGAGATGAC
TTGATTGTGACTCCATTTGCTCAGGTCTTGGCCAGTCTGCGAACTGTACGAAACAACTTT
GCTGCATTAACTAATTTGCAAGATCGAGCACCTAGCAAAAGATCACCCATGTGCAACCAA
CCATCCATCAACAAAGCCACCATAACAGAGGAGGCCTACCAGAAACTGGCCAGCGAGACC
CTGGAGGAGCTGGACTGGTGTCTGGACCAGCTAGAGACCCTACAGACCAGGCACTCCGTC
AGTGAGATGGCCTCCAACAAGTTTAAAAGGATGCTTAATCGGGAGCTCACCCATCTCTCT
GAAATGAGTCGGTCTGGAAATCAAGTGTCAGAGTTTATATCAAACACATTCTTAGATAAG
CAACATGAAGTGGAAATTCCTTCTCCAACTCAGAAGGAAAAGGAGAAAAAGAAAAGACCA
ATGTCTCAGATCAGTGGAGTCAAGAAATTGATGCACAGCTCTAGTCTGACTAATTCAAGT
ATCCCAAGGTTTGGAGTTAAAACTGAACAAGAAGATGTCCTTGCCAAGGAACTAGAAGAT
GTGAACAAATGGGGTCTTCATGTTTTCAGAATAGCAGAGTTGTCTGGTAACCGGCCCTTG
ACTGTTATCATGCACACCATTTTTCAGGAACGGGATTTATTAAAAACATTTAAAATTCCA
GTAGATACTTTAATTACATATCTTATGACTCTCGAAGACCATTACCATGCTGATGTGGCC
TATCACAACAATATCCATGCTGCAGATGTTGTCCAGTCTACTCATGTGCTATTATCTACA
CCTGCTTTGGAGGCTGTGTTTACAGATTTGGAGATTCTTGCAGCAATTTTTGCCAGTGCA
ATACATGATGTAGATCATCCTGGTGTGTCCAATCAATTTCTGATCAATACAAACTCTGAA
CTTGCCTTGATGTACAATGATTCCTCAGTCTTAGAGAACCATCATTTGGCTGTGGGCTTT
AAATTGCTTCAGGAAGAAAACTGTGACATTTTCCAGAATTTGACCAAAAAACAAAGACAA
TCTTTAAGGAAAATGGTCATTGACATCGTACTTGCAACAGATATGTCAAAACACATGAAT
CTACTGGCTGATTTGAAGACTATGGTTGAAACTAAGAAAGTGACAAGCTCTGGAGTTCTT
CTTCTTGATAATTATTCCGATAGGATTCAGGTTCTTCAGAATATGGTGCACTGTGCAGAT
CTGAGCAACCCAACAAAGCCTCTCCAGCTGTACCGCCAGTGGACGGACCGGATAATGGAG
GAGTTCTTCCGCCAAGGAGACCGAGAGAGGGAACGTGGCATGGAGATAAGCCCCATGTGT
GACAAGCACAATGCTTCCGTGGAAAAATCACAGGTGGGCTTCATAGACTATATTGTTCAT
CCCCTCTGGGAGACATGGGCAGACCTCGTCCACCCTGACGCCCAGGATATTTTGGACACT
TTGGAGGACAATCGTGAATGGTACCAGAGCACAATCCCTCAGAGCCCCTCTCCTGCACCT
GATGACCCAGAGGAGGGCCGGCAGGGTCAAACTGAGAAATTCCAGTTTGAACTAACTTTA
GAGGAAGATGGTGAGTCAGACACGGAAAAGGACAGTGGCAGTCAAGTGGAAGAAGACACT
AGCTGCAGTGACTCCAAGACTCTTTGTACTCAAGACTCAGAGTCTACTGAAATTCCCCTT
GATGAACAGGTTGAAGAGGAGGCAGTAGGGGAAGAAGAGGAAAGCCAGCCTGAAGCCTGT
GTCATAGATGATCGTTCTCCTGACACGTAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>809</residue_number>
    <molecular_weight>91114.1</molecular_weight>
    <theoretical_pi>5.537</theoretical_pi>
    <pfams>
      <pfam>
        <name>PDEase_I</name>
        <pfam_id>PF00233</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;cAMP-specific 3',5'-cyclic phosphodiesterase 4D
MEAEGSSAPARAGSGEGSDSAGGATLKAPKHLWRHEQHHQYPLRQPQFRLLHPHHHLPPP
PPPSPQPQPQCPLQPPPPPPLPPPPPPPGAARGRYASSGATGRVRHRGYSDTERYLYCRA
MDRTSYAVETGHRPGLKKSRMSWPSSFQGLRRFDVDNGTSAGRSPLDPMTSPGSGLILQA
NFVHSQRRESFLYRSDSDYDLSPKSMSRNSSIASDIHGDDLIVTPFAQVLASLRTVRNNF
AALTNLQDRAPSKRSPMCNQPSINKATITEEAYQKLASETLEELDWCLDQLETLQTRHSV
SEMASNKFKRMLNRELTHLSEMSRSGNQVSEFISNTFLDKQHEVEIPSPTQKEKEKKKRP
MSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKELEDVNKWGLHVFRIAELSGNRPL
TVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTHVLLST
PALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHHLAVGF
KLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVTSSGVL
LLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGMEISPMC
DKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQSPSPAP
DDPEEGRQGQTEKFQFELTLEEDGESDTEKDSGSQVEEDTSCSDSKTLCTQDSESTEIPL
DEQVEEEAVGEEEESQPEACVIDDRSPDT</protein_sequence>
  </protein_properties>
  <genbank_protein_id>157277988</genbank_protein_id>
  <uniprot_id>Q08499</uniprot_id>
  <uniprot_name>PDE4D_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1E9K</pdb_id>
    <pdb_id>1MKD</pdb_id>
    <pdb_id>1OYN</pdb_id>
    <pdb_id>1PTW</pdb_id>
    <pdb_id>1Q9M</pdb_id>
    <pdb_id>1TB7</pdb_id>
    <pdb_id>1TBB</pdb_id>
    <pdb_id>1XOM</pdb_id>
    <pdb_id>1XON</pdb_id>
    <pdb_id>1XOQ</pdb_id>
    <pdb_id>1XOR</pdb_id>
    <pdb_id>1Y2B</pdb_id>
    <pdb_id>1Y2C</pdb_id>
    <pdb_id>1Y2D</pdb_id>
    <pdb_id>1Y2E</pdb_id>
    <pdb_id>1Y2K</pdb_id>
    <pdb_id>1ZKN</pdb_id>
    <pdb_id>2FM0</pdb_id>
    <pdb_id>2FM5</pdb_id>
    <pdb_id>2PW3</pdb_id>
    <pdb_id>2QYN</pdb_id>
    <pdb_id>3G4G</pdb_id>
    <pdb_id>3G4I</pdb_id>
    <pdb_id>3G4K</pdb_id>
    <pdb_id>3G4L</pdb_id>
    <pdb_id>3G58</pdb_id>
    <pdb_id>3IAD</pdb_id>
    <pdb_id>3IAK</pdb_id>
    <pdb_id>3K4S</pdb_id>
    <pdb_id>3SL3</pdb_id>
    <pdb_id>3SL4</pdb_id>
    <pdb_id>3SL5</pdb_id>
    <pdb_id>3SL6</pdb_id>
    <pdb_id>3SL8</pdb_id>
    <pdb_id>3V9B</pdb_id>
  </pdb_ids>
  <genbank_gene_id>NM_001104631.1</genbank_gene_id>
  <genecard_id>PDE4D</genecard_id>
  <geneatlas_id>PDE4D</geneatlas_id>
  <hgnc_id>HGNC:8783</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Bolger G, Michaeli T, Martins T, St John T, Steiner B, Rodgers L, Riggs M, Wigler M, Ferguson K: A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol. 1993 Oct;13(10):6558-71.</reference_text>
      <pubmed_id>8413254</pubmed_id>
    </reference>
    <reference>
      <reference_text>Nemoz G, Zhang R, Sette C, Conti M: Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells. FEBS Lett. 1996 Apr 8;384(1):97-102.</reference_text>
      <pubmed_id>8797812</pubmed_id>
    </reference>
    <reference>
      <reference_text>Baecker PA, Obernolte R, Bach C, Yee C, Shelton ER: Isolation of a cDNA encoding a human rolipram-sensitive cyclic AMP phosphodiesterase (PDE IVD). Gene. 1994 Jan 28;138(1-2):253-6.</reference_text>
      <pubmed_id>8125310</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bolger GB, Erdogan S, Jones RE, Loughney K, Scotland G, Hoffmann R, Wilkinson I, Farrell C, Houslay MD: Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem J. 1997 Dec 1;328 ( Pt 2):539-48.</reference_text>
      <pubmed_id>9371713</pubmed_id>
    </reference>
    <reference>
      <reference_text>Miro X, Casacuberta JM, Gutierrez-Lopez MD, de Landazuri MO, Puigdomenech P: Phosphodiesterases 4D and 7A splice variants in the response of HUVEC cells to TNF-alpha(1). Biochem Biophys Res Commun. 2000 Aug 2;274(2):415-21.</reference_text>
      <pubmed_id>10913353</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wang D, Deng C, Bugaj-Gaweda B, Kwan M, Gunwaldsen C, Leonard C, Xin X, Hu Y, Unterbeck A, De Vivo M: Cloning and characterization of novel PDE4D isoforms PDE4D6 and PDE4D7.  Cell Signal. 2003 Sep;15(9):883-91.</reference_text>
      <pubmed_id>12834813</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, Jonsdottir T, Gudmundsdottir T, Bjarnadottir SM, Einarsson OB, Gudjonsdottir HM, Hawkins M, Gudmundsson G, Gudmundsdottir H, Andrason H, Gudmundsdottir AS, Sigurdardottir M, Chou TT, Nahmias J, Goss S, Sveinbjornsdottir S, Valdimarsson EM, Jakobsson F, Agnarsson U, Gudnason V, Thorgeirsson G, Fingerle J, Gurney M, Gudbjartsson D, Frigge ML, Kong A, Stefansson K, Gulcher JR: The gene encoding phosphodiesterase 4D confers risk of ischemic stroke.  Nat Genet. 2003 Oct;35(2):131-8. Epub 2003 Sep 21.</reference_text>
      <pubmed_id>14517540</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bolger GB, McCahill A, Yarwood SJ, Steele MR, Warwicker J, Houslay MD: Delineation of RAID1, the RACK1 interaction domain located within the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5. BMC Biochem. 2002 Aug 23;3:24.</reference_text>
      <pubmed_id>12193273</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bolger GB, McCahill A, Huston E, Cheung YF, McSorley T, Baillie GS, Houslay MD: The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins. J Biol Chem. 2003 Dec 5;278(49):49230-8. Epub 2003 Sep 18.</reference_text>
      <pubmed_id>14500724</pubmed_id>
    </reference>
    <reference>
      <reference_text>Richter W, Conti M: The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases. J Biol Chem. 2004 Jul 16;279(29):30338-48. Epub 2004 May 6.</reference_text>
      <pubmed_id>15131123</pubmed_id>
    </reference>
    <reference>
      <reference_text>Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006 Nov 3;127(3):635-48.</reference_text>
      <pubmed_id>17081983</pubmed_id>
    </reference>
    <reference>
      <reference_text>Beausoleil SA, Villen J, Gerber SA, Rush J, Gygi SP: A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol. 2006 Oct;24(10):1285-92. Epub 2006 Sep 10.</reference_text>
      <pubmed_id>16964243</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rosand J, Bayley N, Rost N, de Bakker PI: Many hypotheses but no replication for the association between PDE4D and stroke. Nat Genet. 2006 Oct;38(10):1091-2; author reply 1092-3.</reference_text>
      <pubmed_id>17006457</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yu LR, Zhu Z, Chan KC, Issaq HJ, Dimitrov DS, Veenstra TD: Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra. J Proteome Res. 2007 Nov;6(11):4150-62. Epub 2007 Oct 9.</reference_text>
      <pubmed_id>17924679</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zahedi RP, Lewandrowski U, Wiesner J, Wortelkamp S, Moebius J, Schutz C, Walter U, Gambaryan S, Sickmann A: Phosphoproteome of resting human platelets.  J Proteome Res. 2008 Feb;7(2):526-34. Epub 2007 Dec 19.</reference_text>
      <pubmed_id>18088087</pubmed_id>
    </reference>
    <reference>
      <reference_text>Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, Korner R, Greff Z, Keri G, Stemmann O, Mann M: Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell. 2008 Aug 8;31(3):438-48.</reference_text>
      <pubmed_id>18691976</pubmed_id>
    </reference>
    <reference>
      <reference_text>Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP: A quantitative atlas of mitotic phosphorylation.  Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10762-7. Epub 2008 Jul 31.</reference_text>
      <pubmed_id>18669648</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lee ME, Markowitz J, Lee JO, Lee H: Crystal structure of phosphodiesterase 4D and inhibitor complex(1).  FEBS Lett. 2002 Oct 23;530(1-3):53-8.</reference_text>
      <pubmed_id>12387865</pubmed_id>
    </reference>
    <reference>
      <reference_text>Huai Q, Colicelli J, Ke H: The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry. 2003 Nov 18;42(45):13220-6.</reference_text>
      <pubmed_id>14609333</pubmed_id>
    </reference>
    <reference>
      <reference_text>Huai Q, Wang H, Sun Y, Kim HY, Liu Y, Ke H: Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure. 2003 Jul;11(7):865-73.</reference_text>
      <pubmed_id>12842049</pubmed_id>
    </reference>
    <reference>
      <reference_text>Huai Q, Liu Y, Francis SH, Corbin JD, Ke H: Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity. J Biol Chem. 2004 Mar 26;279(13):13095-101. Epub 2003 Dec 10.</reference_text>
      <pubmed_id>14668322</pubmed_id>
    </reference>
    <reference>
      <reference_text>Xu RX, Rocque WJ, Lambert MH, Vanderwall DE, Luther MA, Nolte RT: Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram. J Mol Biol. 2004 Mar 19;337(2):355-65.</reference_text>
      <pubmed_id>15003452</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhang KY, Card GL, Suzuki Y, Artis DR, Fong D, Gillette S, Hsieh D, Neiman J, West BL, Zhang C, Milburn MV, Kim SH, Schlessinger J, Bollag G: A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell. 2004 Jul 23;15(2):279-86.</reference_text>
      <pubmed_id>15260978</pubmed_id>
    </reference>
    <reference>
      <reference_text>Card GL, England BP, Suzuki Y, Fong D, Powell B, Lee B, Luu C, Tabrizizad M, Gillette S, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY: Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure. 2004 Dec;12(12):2233-47.</reference_text>
      <pubmed_id>15576036</pubmed_id>
    </reference>
    <reference>
      <reference_text>Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, Fong D, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY: A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol. 2005 Feb;23(2):201-7. Epub 2005 Jan 30.</reference_text>
      <pubmed_id>15685167</pubmed_id>
    </reference>
    <reference>
      <reference_text>Huai Q, Sun Y, Wang H, Macdonald D, Aspiotis R, Robinson H, Huang Z, Ke H: Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase. J Med Chem. 2006 Mar 23;49(6):1867-73.</reference_text>
      <pubmed_id>16539372</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wang H, Peng MS, Chen Y, Geng J, Robinson H, Houslay MD, Cai J, Ke H: Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. Biochem J. 2007 Dec 1;408(2):193-201.</reference_text>
      <pubmed_id>17727341</pubmed_id>
    </reference>
    <reference>
      <reference_text>Smith KJ, Baillie GS, Hyde EI, Li X, Houslay TM, McCahill A, Dunlop AJ, Bolger GB, Klussmann E, Adams DR, Houslay MD: 1H NMR structural and functional characterisation of a cAMP-specific phosphodiesterase-4D5 (PDE4D5) N-terminal region peptide that disrupts PDE4D5 interaction with the signalling scaffold proteins, beta-arrestin and RACK1. Cell Signal. 2007 Dec;19(12):2612-24. Epub 2007 Sep 1.</reference_text>
      <pubmed_id>17900862</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wang H, Robinson H, Ke H: The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10. J Mol Biol. 2007 Aug 10;371(2):302-7. Epub 2007 May 26.</reference_text>
      <pubmed_id>17582435</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Dyphylline</name>
        <accession>HMDB14789</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dyphylline</name>
        <accession>HMDB14789</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dyphylline</name>
        <accession>HMDB14789</accession>
      </metabolite>
      <reference>
        <reference_text>Hariton C: Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.</reference_text>
        <pubmed_id>7925603</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketotifen</name>
        <accession>HMDB15056</accession>
      </metabolite>
      <reference>
        <reference_text>Castillo JG, Gamboa PM, Garcia BE, Oehling A: Effect of ketotifen on phosphodiesterase activity from asthmatic individuals.  Allergol Immunopathol (Madr). 1990 Jul-Aug;18(4):197-201.</reference_text>
        <pubmed_id>1702263</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketotifen</name>
        <accession>HMDB15056</accession>
      </metabolite>
      <reference>
        <reference_text>Huang Z, Liu S, Zhang L, Salem M, Greig GM, Chan CC, Natsumeda Y, Noguchi K: Preferential inhibition of human phosphodiesterase 4 by ibudilast.  Life Sci. 2006 May 1;78(23):2663-8. Epub 2005 Nov 28.</reference_text>
        <pubmed_id>16313925</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Iloprost</name>
        <accession>HMDB15220</accession>
      </metabolite>
      <reference>
        <reference_text>Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001 Sep 11;104(11):1218-22.</reference_text>
        <pubmed_id>11551870</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Iloprost</name>
        <accession>HMDB15220</accession>
      </metabolite>
      <reference>
        <reference_text>Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med. 2002 Nov;30(11):2489-92.</reference_text>
        <pubmed_id>12441759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Iloprost</name>
        <accession>HMDB15220</accession>
      </metabolite>
      <reference>
        <reference_text>Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D: Zardaverine and aerosolised iloprost in a model of acute respiratory failure.  Eur Respir J. 2003 Aug;22(2):342-7.</reference_text>
        <pubmed_id>12952271</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Iloprost</name>
        <accession>HMDB15220</accession>
      </metabolite>
      <reference>
        <reference_text>Grant PG, Mannarino AF, Colman RW: cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9071-5.</reference_text>
        <pubmed_id>2461561</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ibudilast</name>
        <accession>HMDB15614</accession>
      </metabolite>
      <reference>
        <reference_text>Huang Z, Liu S, Zhang L, Salem M, Greig GM, Chan CC, Natsumeda Y, Noguchi K: Preferential inhibition of human phosphodiesterase 4 by ibudilast.  Life Sci. 2006 May 1;78(23):2663-8. Epub 2005 Nov 28.</reference_text>
        <pubmed_id>16313925</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
